Alectinib在非小细胞肺癌治疗中的研究进展

doi:10.11904/j.issn.1002-3070.2016.01.016

Abstract

Abstract: Recently,targeted therapy plays an important role in the treatment of non-small cell lung cancer.Crizotinib,the first generation of anaplastic lymphoma kinase(ALK)tyrosine kinase inhibitor,has been approved for the treatment of ALK-rearranged NSCLC in the US since 2011.However,the crizotinib therapy is effective only in the early stage of treatment.After a long time treatment,therapy resistance will follow because of the emerging second mutation of the tumor cell.In recent years,as the second generation of anaplastic lymphoma kinase tyrosine kinase inhibitor,alectinib has been approved in Japan for the treatment of ALK-rearranged NSCLC patients.Thus,research progress of Alectinib for NSCLC therapy is summarized in this article.

Key words: Non-small cell lung carcinoma, EML4-ALK, Drug resistance, Alectinib, Target therapy

CLC Number:

R734.1

PAN Xia, JIANG Jianping. Research progress of Alectinib in the treatment of non-small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 75-79.

References

1 Dhillon S.Gefitinib:a review of its use in adults with advanced non-small cell lung cancer[J].Target Oncol,2015,10(1):153-170.
2 D′Arcangelo M,Wynes MW,Hirsch FR.The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced non-small cell lung cancer[J].Curr Opin Oncol,2013,25(2):121-129.
3 Cole P.Alectinib hydrochloride:ALK receptor tyrosine kinase inhibitor oncolytic[J].Drugs Future,2013,38(12):799-805.
4 Shaw AT,Engleman JA.ALK in lung cancer:past,present,and future[J].J Clin Oncol,2013,31(8):1105-1111.
5 Shaw AT,Kim DW,Nakagawa K,et al.Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J].N Engl J Med,2013,368(25):2385-2394.
6 孔飞飞,姜斌.克里唑替尼在非小细胞肺癌中的研究进展[J].现代肿瘤医学,2013,21(2):433-436.
7 Dziadziuszko R,Jassem J.Beneath the blood brain barrier:the challenge of diagnosis and management of central nervous system involvement in ALK-positive lung cancer[J].J Thorac Oncol,2013,8(12):1465-1466.
8 Awad MM,Sahaw AT.ALK inhibitors in non-small cell lung cancer:crizotinib and beyond[J].Clin Adv Hematol Oncol,2014,12(7):429-439.
9 Dhillon S,Clark M.Ceritinib:first global approval[J].Drugs,2014,74(11):1285-1291.
10 Yoneshima Y,Okamoto I,Takano T,et al.Successful treatment with alectinib after crizotinib-induced esophageal ulceration[J].Lung Cancer,2015,88(3):349-351.
11 Sakamoto H,Tsukaguchi T,Hiroshima S,et al.CH5424802,a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant[J].Cancer Cell,2011,19(5):679-690.
12 Latif M,Saeed A,Kim SH.Journey of the ALK-inhibitor CH5424802 to phase II clinical tria[J].Arch Pharm Res,2013,36(9):1051-1054.
13 Inamura K,Takeuchi K,Togashi Y,et al.EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers[J].J Thorac Oncol,2008,3(1):13-17.
14 Kodama T,Tsukaguchi T,Yoshida M,et al.Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance[J].Cancer Lett,2014,351(2):215-221.
15 刘春花,宋勇.克唑替尼在非小细胞肺癌治疗中的研究进展[J].中华肺部疾病杂志,2014,7(1):78-80.
16 Kodama T,Hasegawa M,Takanashi K,et al.Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases[J].Cancer Chemother Pharmacol,2014,74(5):1023-1028.
17 Toyokawa G,Seto T.Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance:clinical and preclinical data[J].Oncol Res Treat,2015,38(6):291-298.
18 lqnatius Ou SH,Azada M,Hsiang DJ,et al.Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib(CH5424802/RO5424802)in ALK-rearranged NSCLC patients who progressed on crizotinib[J].J Thorac Oncol,2014,9(4):549-553.
19 Tanimoto A,Yamada T,Nanjo S,et al.Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells[J].Oncotarget,2014,5(13):4920-4928.
20 Seto T,Kiura K,Nishio M,et al.CH5424802(RO5424802)for patients with ALK-rearranged advanced non-small-cell lung cancer(AF-001JP study):a single-arm,open-label,phase 1-2 study[J].Lancet Oncol,2013,14(7):590-598.
21 McKeage K.Alectinib:A review of its use in advanced ALK-rearranged non-small cell lung cancer[J].Drugs,2015,75(2):75-82.
22 Gadgeel SM,Gandhi L,Riely GJ,et al.Safety and activity of alectinib against systemic disease and brain metastases inpatients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer(AF-002JG):results from the dose-finding portion of a phase 1/2 study[J].Lancet Oncol,2014,15(10):1119-1128.
23 Toyokawa G,Seto T.ALK inhibitors:what is the best way to treat patients with ALK⁺ non-small-cell lung cancer?[J].Clin Lung Cancer,2014,15(5):313-319.

[1]	LI Yue, XU Ke, HAN Zengxiang, SUN Min, FAN Guohua, ZHANG Yong. Advances in the role of tumor-associated macrophage in colon cancer and targeted therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 450-454.
[2]	SUN Lina, ZHAO Xiaodi, LU Yuanyuan, WANG Xin. Research progress of LncRNA and chemotherapy resistance in gastrointestinal neoplasms [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 448-453.
[3]	HUANG Chenglu, HAN Shaohui, XU Suqin, ZHAO Jungang. The research progress of primary pulmonary mucinous adenocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 463-467.
[4]	ZENG Yulan,LIU Yangyang,LIANG Jinyan,GU Feifei,LIU Li. Advances in drug resistance mechanism of immunological checkpoint inhibitors and post-drug resistant therapeutic strategy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 353-358.
[5]	HUANG Jian,PANG Hui,SONG Yuhang,CAI Li. The role of microRNA in drug resistance of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 272-276.
[6]	DUAN Peiwen, ZHAO Miaomiao, WANG Songpo. The recent advances in the research of NF-κB in the development and relevant treatment of the colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 43-47.
[7]	ZHAO Yu,ZHU Xiaoting,WANG Yinan. The role and mechanisms of ω-3 polyunsaturated fatty acids in inducing cell apoptosis and anti-proliferation in multiple myeloma [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 516-522.
[8]	REN Tingting,XING Ying,MENG Qingwei. Progress in association between autophagy and cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 543-546.
[9]	ZHAO Xiangxuan, WEN Feng, MAO Xiaonan, LU Zaiming. Study advances on the roles of apoptosis in hepatocellular carcinoma therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 448-452.
[10]	ZHAO Xiangxuan,WEN Feng,LU Zaiming. The role of apoptosis in pancreatic cancer therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 375-379.
[11]	LIU Wei,LI Huiyan. Progress in relationship between epidermal growth factor receptor and radiosensitivity [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(3): 275-278.
[12]	CHI Shuqi, WANG Hongbo. LncRNAs and drug resistance in tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 150-153.
[13]	ZHANG Wei,WU Jin. The research progress on cancer multidrug resistance mechanisms [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 364-367.
[14]	XU Ruirui,WEN Liyuan,SUN Guoqiang,MENG Qingwei,SUN Lichun,CAI Li. Research on the expression of Caveolin-1 with EGFR mutations in non-small cell lung cancer tissues and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 498-502.
[15]	CHEN Kexin,LI Chen,QIN Yu,YAO Guodong,GENG Jingshu. Advances in AEG-1 mediated drug resistance [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(5): 447-450.

Research progress of Alectinib in the treatment of non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments